

Datasheet for ABIN1589703
anti-FLT4 antibody



[Go to Product page](#)

1 Publication

Overview

Quantity:	100 µg
Target:	FLT4
Reactivity:	Human
Host:	Mouse
Clonality:	Monoclonal
Conjugate:	This FLT4 antibody is un-conjugated
Application:	Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Product Details

Purpose:	VEGFR-3/FLT-4 antibody
Immunogen:	Recombinant human soluble VEGFR-3/FLT-4
Clone:	9D9
Isotype:	IgG1
Specificity:	Recombinant human soluble VEGFR-3/FLT-4
Cross-Reactivity (Details):	The antibody will detect native human VEGFR-1/Flt-1 in ELISA experiments, WB, IF and IP.
Characteristics:	Chromosomal location: 5q35.3 This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified recombinant human Vascular Endothelial Growth Factor Receptor 3 (recombinant human VEGFR-3/FLT-4) extracellular domain.

Product Details

Purification: Protein-G affinity chromatography

Target Details

Target: FLT4

Alternative Name: VEGFR-3/FLT-4 ([FLT4 Products](#))

Background: Vascular endothelial growth factor receptor-3, FLT4, PCL, LMPH1A, VEGFR3, fms-related tyrosine kinase 4, VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk 1) and VEGFR-3 (FLT-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular and lymphatic endothelial cells and to the monocyte/macrophage lineage. These receptors play essential roles in vasculogenesis, hematopoiesis, angiogenesis and lymphangiogenesis. The VEGFR-3 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 24 aa residue signal peptide. Mature VEGFR-3 is composed of a 751 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 482 aa residue cytoplasmic domain. Both VEGF-C and VEGF-D have been shown to bind and activate VEGF R3 (Flt-4). The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stage of development. It is important for lymphangiogenesis.

Gene ID: 2324

NCBI Accession: [NM_002020, NP_002011](#)

UniProt: [P35916](#)

Pathways: [RTK Signaling, Signaling Events mediated by VEGFR1 and VEGFR2, VEGF Signaling](#)

Application Details

Application Notes: ELISA: Use at 1-5 µg/mL, Western Blot: Use at 1-5 µg/mL, IF/ IHC: Use at 1-10 µg/mL.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/mL.

Handling

Buffer:	PBS
Handling Advice:	Centrifuge vial prior to opening.
Storage:	4 °C,-20 °C
Storage Comment:	The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.
Expiry Date:	24 months

Publications

Product cited in:	Rohringer, Holnthoner, Hackl, Weihs, Rünzler, Skalicky, Karbiener, Scheideler, Pröll, Gabriel, Schweighofer, Gröger, Spittler, Grillari, Redl: "Molecular and cellular effects of in vitro shockwave treatment on lymphatic endothelial cells." in: PLoS ONE , Vol. 9, Issue 12, pp. e114806, (2014) (PubMed).
-------------------	---